Xeris Biopharma Holdings, Inc.
XERS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $203 | $164 | $110 | $50 |
| % Growth | 23.9% | 48.7% | 122.3% | – |
| Cost of Goods Sold | $37 | $29 | $23 | $13 |
| Gross Profit | $166 | $135 | $88 | $36 |
| % Margin | 81.9% | 82.5% | 79.5% | 73.1% |
| R&D Expenses | $26 | $22 | $21 | $25 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $163 | $146 | $138 | $126 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $11 | $11 | $11 | $1 |
| Operating Expenses | $200 | $179 | $170 | $151 |
| Operating Income | -$34 | -$44 | -$82 | -$115 |
| % Margin | -16.6% | -26.8% | -74.3% | -232.2% |
| Other Income/Exp. Net | -$23 | -$19 | -$14 | -$8 |
| Pre-Tax Income | -$57 | -$64 | -$96 | -$123 |
| Tax Expense | -$2 | -$1 | -$1 | $0 |
| Net Income | -$55 | -$62 | -$95 | -$123 |
| % Margin | -27% | -38% | -85.9% | -247.5% |
| EPS | -0.37 | -0.45 | -0.7 | -1.55 |
| % Growth | 17.8% | 35.7% | 54.8% | – |
| EPS Diluted | -0.37 | -0.45 | -0.7 | -1.55 |
| Weighted Avg Shares Out | 147 | 138 | 136 | 79 |
| Weighted Avg Shares Out Dil | 147 | 138 | 136 | 79 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5 | $5 | $3 | $0 |
| Interest Expense | $33 | $27 | $14 | $7 |
| Depreciation & Amortization | $13 | $13 | $13 | $2 |
| EBITDA | -$14 | -$24 | -$69 | -$114 |
| % Margin | -6.9% | -14.5% | -62.9% | -229.2% |